Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats

Summary

In a rat model of lipopolysaccharide (LPS)-induced disseminated intravascular coagulation (DIC), we used urokinase (UK) in an attempt to clarify the role of fibrinolysis and to investigate changes in plasma endothelin levels. Two kinds of experiment were performed. The first one: experimental DIC was induced by sustained infusion of 30 mg/kg LPS for 4 h via the tail vein, and two doses of UK (2.0 or 10.0 IU/g/4.5 h) were administered to rats 30 min before infusion of LPS, after which UK infusion was continued for a further 4 h. The second one: experimental DIC was induced by sustained infusion of 1 mg/kg/10 min LPS for 10 min, and two doses of UK (2.0 or 10.0 IU/g/4 h) were administered to rats at 30 min after LPS infusion. The parameters described below were determined at 4 h in the first experiment, at 4 h and 8 h in the second one. The similar results were observed in both kinds of experiment. There were no significant differences in plasma thrombin-antithrombin complex, fibrinogen or platelet number among the three DIC groups, in both kinds of experiment. Plasma levels of D-dimer were significantly increased in the LPS + higher dose of UK group when compared with the LPS group. The increased plasma plasminogen activator inhibitor (PAI) activity seen in the LPS group was significantly suppressed in the groups receiving UK (especially higher dose of UK). In addition, the increased plasma levels of creatinine and alanine aminotransferase seen in the LPS group were significantly suppressed in the groups receiving UK (especially higher dose of UK). Plasma levels of endothelin, known to be a potent vasoconstrictive agent, were markedly elevated by LPS infusion, and were significantly suppressed in the groups receiving UK of both kinds of experiment, in a dose-dependent fashion compared with LPS group. Glomerular fibrin deposition was significantly suppressed in the groups receiving UK when compared with the LPS group. No manifestations of bleeding were observed in any of the groups. Enhanced fibrinolysis and depressed endothelin induced by UK thus appear to play an important role in preventing the development of organ failure in the LPS-induced DIC model.

Keywords

DIC - urokinase - fibrinolysis - endothelin

• References

• 1 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
• 2 Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998; 24: 3-18.
• 3 Toh CH, Dennis M. Disseminated intravascular coagulation: old disease, new hope. Br Med J 2003; 327: 974-7.
• 4 Takahashi H, Tatewaki W, Wada K. et al. Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 1990; 33: 90-5.
• 5 Asakura H, Jokaji H, Saito M. et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis 1994; 5: 829-32.
• 6 Matsuda T. et al. Changes in levels of t-PA and alpha 2PI-plasmin complex in plasma in patients with DIC. Thromb Res 1988; (Suppl. 08) 143-51.
• 7 Dombret H. et al. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995; 9: 19-24.
• 8 Paramo JA, Fernandez Diaz FJ. et al. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemost 1988; 59: 451-4.
• 9 Levi M. et al. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16: 43-7.
• 10 Asakura H. et al. Marked difference in pathophysiology between tissue factor- and lipopolysaccharideinduced disseminated intravascular coagulation models in rats. Crit Care Med 2002; 30: 161-4.
• 11 Asakura H. et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide- induced DIC models in rats. Blood Coagul Fibrinolysis 2003; 14: 221-8.
• 12 Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 167–71. 1 integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ib α. J Biol Chem 2001; 276: 25121-6.
• 13 Levin ER, Endothelins N. N Engl J Med 1995; 333: 356-363
• 14 Ishibashi M, Saito K, Watanobe K. et al. Plasma endothelin- 1 levels in patients with disseminated intravascular coagulation. N Engl J Med 1991; 324: 1516-7.
• 15 Asakura H, Jokaji H, Saito M. et al. Role of endothelin in disseminated intravascular coagulation. Am J Hematol 1992; 41: 71-5.
• 16 Yanagisawa M, Kurihara H, Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
• 17 Wanecek M. et al. The endothelin system in septic and endotoxin shock. Eur J Pharmacol 2000; 407: 1-15.
• 18 Asakura H. et al. Induction of vasoactive substances differs in LPS-induced and TF-induced DIC models in rats. Thromb Haemost 2002; 88: 663-7.
• 19 Pelzer H. et al. Determination of human thrombinantithrombin III complex in plasma with an enzymelinked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
• 20 Suzuki N, Matsumoto H, Kitada C. et al. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods 1989; 118: 245-50.
• 21 Kawasaki H, Hayashi K, Awai M. Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues. Acta Pathol Jpn 1987; 37: 77-84.
• 22 Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thromb Res 1992; 65: 785-90.
• 23 Taylor Jr FB. et al. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.
• 24 Kaddoura S, Curzen NP, Evans TW. et al. Tissue expression of endothelin-1 mRNA in endotoxaemia. Biochem Biophys Res Commun 1996; 218: 641-7.
• 25 Suga Y, Asakura H, Yoshida T. et al. Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist. Blood Coagul Fibrinolysis 2004; 15: 593-8.
• 26 Lechleitner P, Genser N, Mair J. et al. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem 1993; 39: 955-9.
• 27 Battistelli S. et al. Behavior of circulating endothelin- 1 in a group of patients with acute myocardial infarction. Angiology 1999; 50: 629-38.
• 28 Yamada Y, Yokota M. Direct interactions of plasminogen activators with human aortic and pulmonary artery endothelial cells in vitro: implications for thrombolytic therapy. J Cardiovasc Pharmacol 1996; 27: 629-35.
• 29 Schnermann JB, Zhu XL, Shu X. et al. Regulation of endothelin production and secretion in cultured collecting duct cells by endogenous transforming growth factor-beta. Endocrinology 1996; 137: 5000-8.
• 30 Schneider J. Fibrin-specific lysis of microthrombosis in endotoxemic rats by saruplase. Thromb Res 1993; 72: 71-82.
• 31 Paloma MJ. et al. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality. Thromb Haemost 1995; 74: 1578-82.
• 32 Munoz MC. et al. Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. Br J Haematol 1999; 105: 117-21.